Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.

Transcription

1 Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.

2 The purpose of this presentation Looking for Joint Venture Development across multiple therapeutic areas (TA) including Oncology, Neurology and rare diseases. Asset Management Partnership. We have 118 different products to move forward with. Reciprocal and Mutual Development. Address the unmet medical needs, hard to treat chronic and terminal illness via a vision of value based health care. Impacting the most number of patients globally with the best potential clinical outlook.

3 Index Who are we? Introduction to our family of companies. What is our technology all about? Introduction to our technology, ongoing early and late stage research and development (R&D), scientific, clinical, and business basis of our value- proposition. Proven data of the clinical data, our scientific foundation, and the core of its health care centric output. Facts and Figures, no projection and conjectures. Roadmap to our success. Timeline and milestones. Therapeutic areas, drug families across multiple areas including Oncology, Neurology and rare disease (cannabis extracts included).

4 Preview Who are we? Three(3) Companies one Mission 1. Global Allied Pharmaceuticals, LLC. ( 2. Nexus Alliance Biopharmaceuticals, LLC. ( 3. Lior Biosciences. LLC. ( 4. The home to Specific Conjugated Particles (SCP). Antibody Drug Conjugate (ADC) spin- off. 5. Multiple intellectual property protected technology and innovations. 6. Three companies, one management team, with one mission in focus. 7. Mission: A real value- based health care via our innovative clinical/ip protected technology in biopharma. Treat the neediest, with the least financial burden, and the quickest possible. Devil is in details. Knowledge is power

5 Value- based Technology 1) Proven track record in development. History of Research and Development in Biopharma for the past 14 years in biopharmaceuticals R&D. 2) A robust and well credentialed team of MD scientists in providing the next generation bioavailability tool. 3) An expanded and life Cycle Intellectual property. Specific Conjugated Particles (SCP) technology. 4) In Benchmark and First in Human Data, as well as expanded access data. Multiple trials and clinical data from compassionate use. 5) To scale up a pipeline and manufacturing at a cost- contained level. Nothing like liposomes of Nanomedicine. We are well sustained as improve the safety and efficacy by factors of 10X. 6) In existing revenue stream with an expanded upshot growth in immediate and intermediate prospective. 7) In expanding the existing products into their Repurposed indications including unmet metical needs and rare disease as well as rare tumors in Oncology

6 GAP A Contract Research Organization serving small, medium and large companies for the past 14 years. Started as a one many operation, and led into a global BPO, CRO, and technology development service provider. Clinical operations, development, medical communication, as well as AI technologies have been our edge of development. GAP has worked on formulation products with many sponsors. Available for potential services associated with our core competencies in Oncology, neurology and rare diseases.

7 NAB Nexus Alliance Biopharmaceuticals (NAB), Global Allied Pharmaceuticals (GAP), and Lior Biosciences (LB). Three companies one body. NAB owns and has developed its patents and its products. NAB out- licensed its IP to LB for the exclusive purposes of cannabis extracts. GAP is a Global turn- key CRO and BPO. NAB and LB are early asset development research and development companies. Two companies with proven track record for 18 and 10 years; GAP and NAP, respectively. GAP and NAB are US funded/based. The potential licensing opportunities for our Specific Conjugate Particles(SCP) and future Antibody Drug Conjugate(ADC) platforms fits with IO and combination strategies( and

8 Lior Biosciences In licensed SCP from NAB, developed supplements from its technology in cannabis extracts/cbd/trepans leading into its current revenue generations. Initiating RX- R&D in specific targeted therapeutic areas in unmet medical needs as well as orphan drug applications. A potential $3B discovery initiative with a projected and current approach against the current space. Looking for partners.

9 Team Summary COMPANY HISTORY Founded in 1998 by Timothy Allen, MD, PhD Nexus Alliance Pharmaceuticals is a niche clinical research and discovery company R&D PLATFORM Nexus proprietary SCP technology is an innovative platform to significantly enhance therapeutic effect of molecules by increasing bioavailability and activity and reducing side effects 5 SCP assets in clinical stage 120 investigational ready to enter clinical stage. We are working on the second generation ADC and SCP platform at the moment. MANUFACTURING FACILITIES Nexus has acquired Two formulation facilities: 4 Manufacturing plants Experience in development and production (25 branded and >100 generic formulations)

10 The Winning team Clinical And Scientific Management President and CEO. Nepton Sheikh- Allen, MD: She is A trained MD with fellowship on clinical research in Hem. Oncology. She has led 7 NDAs with 18 INDs over the last 12 years. Nepton worked through her ranks from a clinical research associate, a safety MD into therapeutic lead, VP of GAP, Sr. VP of NAB, finally the President and CEO of NAB. She has authored 6 peer review papers, close to 88 white papers, as well as provided clinical and technical presentations with noted groups including Drug Information Association (DIA), American Society of Clinical Oncology (ASCO), etc. She has an extensive background filing the safety sections of multiple NDAs with background in aggregate reporting in safety and surveillance with multiple health authorities (HAs); including FDA and EMA, as well as other notified bodies. She has a consistent proven track record in Drug Safety, surveillance, and signaling, as well as Global Pharmacovigilance (GPV), notified bodies' negotiation and responses, REMS development/initiation/observation. She has a solid experience in Clinical Development, Medical Affairs, as well as product acquisition are to name a few core space of success. Chief Medical Officer. Ghazaleh Shoja, MD: She is a trained MD in medicine and Hem. Oncology with fellowship in bone marrow transplantation. She has worked as a practicing MD for the past 25 years and as a clinical researcher with ample experience in launching IND, NDA as well as BLAs with the Has, including FDA and EMA. She has published extensively with more than 24 peer review papers, co- authored 1 book, and currently leads a clinical medicine group in Canada, works as the lead interface clinician with the HAs as well as the Qualified Person with Health Canada. She has led multiple clinical trails as principle investigator as well as sub- investigator in her experience in clinical medicine. Founder Chief Scientific Officer. Timothy Allen, MD, PhD: A trained MD in medicine and Hem. Oncology, subfellowship in Immune Oncology, and PhD in Epidemiology. He has 14 years of experience in research and practice, a current CIOMS contributor and an ex- fellow at FDA. He advises HAs. A known contributor in Immune Oncology, combination therapy, ADC, as well as GPV. He has led multiple INDs, NDAs, and BLAs. He has authored more than 64 peer review papers, two text books in GPV and Immune- Oncology. He primarily works on rare tumors and unmet medical needs in treatment of Malignancies. Additional team leaders not mentioned: A well qualified and experienced group of skilled professionals.

11 Vision & Strategy Vision. Displace current classic mainstay therapies with enhanced SCP-molecules Development Strategy Modification only of known generics into branded asset of SCP-X to avoid need of acquisition of new assets Regulatory environment FDA: 505(b2) process 16 moieties with Orphan Drug Designation (ODD) 9 moieties available for patent-extension EMA: ANDA process Value proposition Increase in efficacy and safety profile with low development in generic environment enables optimal competitive value proposition

12 Technical and Scientific data and its achievement A proven technology of SCP: I. A 12 years and $14M benchmark R&D from its early stage to late stage of benchmark. II. A technical achievement in reformulation and repurposing for close to 124 products up to now. III. Providing a venue to tackle first line of therapy as well as combination therapy in complement the standard of care. An absolute and practical solution to tackle rare diseases today. IV. Visit: technology-page/ A proven track record in SCP- Oncology: I. Its marvel achievement in combination therapy in increasing the dose, frequency and regimented schedules including follow-up/maintenance treatments. II. The trendsetting proven track record in the clinical data, application to many tumor states and disease states, as well as rare tumors. III. Providing the only opportunity to treat rare tumors and relapsed/refractory late stage patients with no alternate treatments available. IV. Visit: A proven application of SCP- Cannabis extracts: I. A ventured space into RX, OTC, and supplements. II. A ground breaking clinical data, a progressive current financial success story, and its current Revenue Stream. III. Visit:

13 Why Us? Two current platforms of SCP and ADC: A wealth of pipeline. A turn key launching opportunity. We are a formulation based and a clinical development group team. Proven track record: We have 125 innovative investigational assets under one roof and one IP development. All ready to enter clinical stage. All post bench- mark proof of their proven concept sheets. All along the same as clinically proven assets. All SCP assets follow 505 B(2) route. Between SCP- clinically proven, and SCP bench mark, as well as ADC, we are a year prospective partner with the healthiest pipeline ever. Additional next Generation Asset management post SCP technology in line to roll out: We are developing the next generation ADC platform at the moment.

14 Questions Please contact: Timothy Allen, MD, PhD. SVP- CMO. Board Member. Global Lead Clinician, Clinical Development and Medical Affairs Tele#: Skype ID: timallenmed1